Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Total Current Liabilities (2021 - 2025)

Valion Bio has reported Total Current Liabilities over the past 5 years, most recently at $646000.0 for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 137.5% year-over-year to $646000.0; the TTM value through Dec 2025 reached $646000.0, up 137.5%, while the annual FY2025 figure was $646000.0, 137.5% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $646000.0 at Valion Bio, up from $638000.0 in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $2.4 million in Q2 2022 and troughed at $272000.0 in Q4 2024.
  • A 5-year average of $1.1 million and a median of $1.0 million in 2023 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: plummeted 80.59% in 2024 and later skyrocketed 137.5% in 2025.
  • Year by year, Total Current Liabilities stood at $1.2 million in 2021, then skyrocketed by 54.06% to $1.9 million in 2022, then decreased by 25.4% to $1.4 million in 2023, then plummeted by 80.59% to $272000.0 in 2024, then skyrocketed by 137.5% to $646000.0 in 2025.
  • Business Quant data shows Total Current Liabilities for TIVC at $646000.0 in Q4 2025, $638000.0 in Q3 2025, and $821000.0 in Q2 2025.